August 27, 2025 — Leads & Copy — enGene Holdings Inc. (Nasdaq: ENGN) will participate in investor conferences in September, including the Wells Fargo Healthcare Conference on Sept. 3 at 8:45 a.m. ET, the H.C. Wainwright 27th Annual Global Investment Conference on Sept. 8 at 1:30 p.m. ET, and the Morgan Stanley 23rd Annual Global Healthcare Conference on Sept. 10 at 1:50 p.m. ET.
A live webcast of these events can be accessed under the “Investors” section of the enGene website and will be archived there for 90 days.
enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead program is detalimogene voraplasmid for patients with Non-Muscle Invasive Bladder Cancer, being evaluated in the LEGEND Phase 2 trial.
To learn more, please visit enGene.com and follow us on LinkedIn, X and BlueSky.
Source: enGene
